Gerovital-H3: a clinical trial as an antidepressant
- PMID: 376578
- DOI: 10.1093/geronj/33.4.514
Gerovital-H3: a clinical trial as an antidepressant
Abstract
Twenty-five volunteers, all in their fifth decade or beyond, all with mild to moderate, nonpsychotic depression of at least several months' duration participated in a double-blind study of Gerovital vs placebo. There was no significant difference between the Gerovital and placebo groups; both groups showed significant improvement on self-rating as well as observer rating scales.
Similar articles
-
Effects of a procaine preparation (Gerovital H3) in hospitalized geriatric patients: a double-blind study.J Am Geriatr Soc. 1975 Aug;23(8):355-9. doi: 10.1111/j.1532-5415.1975.tb00326.x. J Am Geriatr Soc. 1975. PMID: 1097490 Clinical Trial.
-
A trial of Gerovital H-3 in depression during senility.Curr Ther Res Clin Exp. 1974 Jan;16(1):59-63. Curr Ther Res Clin Exp. 1974. PMID: 4203849 Clinical Trial. No abstract available.
-
Treatment of depression in the aged with gerovital H3: clinical efficacy and neurophysiological effects.Psychopharmacol Bull. 1976 Apr;12(2):50-1. Psychopharmacol Bull. 1976. PMID: 769036 Clinical Trial. No abstract available.
-
Outcome criteria in antidepressant drug trials: self-rating versus observer-rating scales.Pharmacopsychiatry. 1991 May;24(3):71-5. doi: 10.1055/s-2007-1014442. Pharmacopsychiatry. 1991. PMID: 1891483 Review.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
Comprehensive exploration of the anticancer activities of procaine and its binding with calf thymus DNA: a multi spectroscopic and molecular modelling study.RSC Adv. 2018 Mar 1;8(17):9083-9093. doi: 10.1039/c7ra13647a. eCollection 2018 Feb 28. RSC Adv. 2018. PMID: 35541873 Free PMC article.